Heidelberg Pharma to Receive Milestone Payment from Partner Huadong for Clinical Study with HDP-101 in China
- First patient dosed in Huadong’s Phase I study with HDP-101 in China
- Trial will evaluate safety, tolerability, pharmacokinetics and efficacy of HDP-101 in Chinese population with plasma cell disorders including multiple myeloma
Ladenburg, Germany, 18 March 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that its partner Huadong Medicine Co., Ltd., Hangzhou, China, (SZ 000963; Huadong) has reached a development milestone under the terms of the license agreement from February 2022. With the dosing of the first patient in a clinical study with HDP-101 (INN: pamlectabart tismanitin) in China, a planned milestone payment to Heidelberg Pharma became due and is being processed. Financial details were not disclosed.
The clinical Phase I trial will evaluate the safety, tolerability, pharmacokinetics and efficacy of Heidelberg Pharma’s lead ATAC candidate pamlectabart tismanitin in Chinese population with plasma cell disorders including multiple myeloma. This bridging study is conducted in addition to the existing clinical program with this ATAC to ensure that safety and efficacy of the ATAC is comparable across diverse populations. The study has initiated dosing at 140 µg/kg, a dose level previously shown to be safe and well tolerated in the Caucasian ethnicity.
Dr. Donghzou Jeffery Liu, Chief Executive Officer of Heidelberg Pharma AG, commented: “The start of clinical development in China is an important milestone for us and Huadong, enabling us to test this product candidate not only in Europe and the US but also in Asia. With our unique payload Amanitin we have a clear differentiation in the ADC space. We are confident that pamlectabart tismanitin will demonstrate consistent safety and tolerability in the Chinese population and firmly believe in its therapeutic potential for various patient groups.”
